In this issue:
TNF inhibitors + DMARDs for RA
Sifalimumab for SLE
Cost-effectiveness of adalimumab/ etanercept dose optimisation in RA
Certolizumab pegol vs adalimumab for RA
Ustekinumab for CD induction and maintenance
DNA, RNA and protein biomarkers to predict anti-TNF response
TNFi therapy and complication risk after ileal pouch-anal anastomosis
Invasive melanoma in biologic treated RA patients
Please login below to download this issue (PDF)